In the biopharma financing arena, several substantial fundraises and strategic corporate moves were reported. Kriya Therapeutics raised $313 million to advance gene therapies for chronic diseases utilizing AAV vectors despite recent safety concerns in the field. QuidelOrtho completed a $3.4 billion debt refinancing aimed at improving financial flexibility. Calidi Biotherapeutics closed a $6.9 million public offering supporting targeted genetic medicines. Additionally, BioTools Innovator awarded up to $1 million in funding to five companies focusing on public health emergency preparedness, underpinning government's ongoing investment in health security technology development.